Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With Hepatic Arterial Infusion Chemotherapy (HAIC) in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy

NCT05511051 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT05511051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05511051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With Hepatic Arterial Infusion Chemotherapy (HAIC) in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Phase 2
Overall status
Unknown status
Start date
February 1, 2022
Completion date
December 31, 2024
Enrollment
102 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer